MX2019000962A - Novedosas proteinas de la capside del virus adenoasociado. - Google Patents
Novedosas proteinas de la capside del virus adenoasociado.Info
- Publication number
- MX2019000962A MX2019000962A MX2019000962A MX2019000962A MX2019000962A MX 2019000962 A MX2019000962 A MX 2019000962A MX 2019000962 A MX2019000962 A MX 2019000962A MX 2019000962 A MX2019000962 A MX 2019000962A MX 2019000962 A MX2019000962 A MX 2019000962A
- Authority
- MX
- Mexico
- Prior art keywords
- capsid proteins
- associated virus
- novel
- virus capsid
- novel adeno
- Prior art date
Links
- 108090000565 Capsid Proteins Proteins 0.000 title abstract 6
- 102100023321 Ceruloplasmin Human genes 0.000 title abstract 6
- 241000702421 Dependoparvovirus Species 0.000 title abstract 2
- 239000013607 AAV vector Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366838P | 2016-07-26 | 2016-07-26 | |
| PCT/US2017/043703 WO2018022608A2 (en) | 2016-07-26 | 2017-07-25 | Novel adeno-associated virus capsid proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000962A true MX2019000962A (es) | 2019-08-01 |
Family
ID=59558468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000962A MX2019000962A (es) | 2016-07-26 | 2017-07-25 | Novedosas proteinas de la capside del virus adenoasociado. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11584780B2 (enExample) |
| EP (1) | EP3491008A2 (enExample) |
| JP (4) | JP6994018B2 (enExample) |
| KR (2) | KR20230161535A (enExample) |
| CN (1) | CN109715650B (enExample) |
| AU (2) | AU2017301600B2 (enExample) |
| BR (1) | BR112019001532A2 (enExample) |
| CA (1) | CA3031026A1 (enExample) |
| CL (6) | CL2019000167A1 (enExample) |
| IL (2) | IL263801B2 (enExample) |
| MX (1) | MX2019000962A (enExample) |
| PE (1) | PE20190401A1 (enExample) |
| PH (1) | PH12019500068A1 (enExample) |
| SG (1) | SG11201811603WA (enExample) |
| WO (1) | WO2018022608A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| IL314171A (en) | 2015-09-28 | 2024-09-01 | Univ Florida | Methods and compositions for antibody-evading virus vectors |
| WO2018039375A1 (en) | 2016-08-23 | 2018-03-01 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| IL325122A (en) | 2018-02-22 | 2026-02-01 | Akouos Inc | Compositions and methods for treating non-age-related hearing impairment in humans |
| EP3768695A4 (en) * | 2018-02-27 | 2022-04-06 | The Trustees of the University of Pennsylvania | NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF |
| MX2020010465A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| BR112020020266A2 (pt) | 2018-04-03 | 2021-01-19 | Stridebio, Inc. | Vetores de vírus com evasão de anticorpos |
| CA3095179A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| JP7374119B2 (ja) * | 2018-04-05 | 2023-11-06 | ジェネトン | 減少した肝臓向性を有するＡＡＶ９とＡＡＶｒｈ７４とのハイブリッド組換えアデノ随伴ウイルス血清型 |
| WO2019200016A1 (en) | 2018-04-10 | 2019-10-17 | President And Fellows Of Harvard College | Aav vectors encoding clarin-1 or gjb2 and uses thereof |
| KR20210008501A (ko) | 2018-05-09 | 2021-01-22 | 바이오마린 파머수티컬 인크. | 페닐케톤뇨증을 치료하는 방법 |
| IL278598B2 (en) * | 2018-05-11 | 2025-11-01 | Massachusetts Eye & Ear Infirmary | Altering tissue tropism of adeno-associated viruses |
| TW202005978A (zh) * | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| US11821009B2 (en) | 2018-05-15 | 2023-11-21 | Cornell University | Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery |
| US12195745B2 (en) | 2018-08-21 | 2025-01-14 | Massachusetts Eye And Ear Infirmary | Compositions and methods for modulating transduction efficiency of adeno-associated viruses |
| CN113613668A (zh) | 2018-10-24 | 2021-11-05 | 百时美施贵宝公司 | 小型化肌营养不良蛋白及其用途 |
| BR112021009913A2 (pt) * | 2018-12-05 | 2021-08-17 | Abeona Therapeutics, Inc. | vetor viral adeno-associado recombinante para inserção gênica |
| WO2020154535A1 (en) | 2019-01-23 | 2020-07-30 | University Of Florida Research Foundation, Incorporated | Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design |
| CN113727992A (zh) | 2019-03-21 | 2021-11-30 | 斯特里迪比奥公司 | 重组腺相关病毒载体 |
| JP7659271B2 (ja) * | 2019-03-28 | 2025-04-09 | ザ ジェネラル ホスピタル コーポレイション | 導入遺伝子発現のための操作されたアデノ随伴（ａａｖ）ベクター |
| CN114450411A (zh) | 2019-04-01 | 2022-05-06 | 特纳亚治疗股份有限公司 | 具有工程化衣壳的腺相关病毒 |
| WO2020232044A1 (en) | 2019-05-14 | 2020-11-19 | Biomarin Pharmaceutical Inc. | Methods of redosing gene therapy vectors |
| CA3153972A1 (en) | 2019-09-09 | 2021-03-18 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav |
| WO2021073568A1 (en) * | 2019-10-16 | 2021-04-22 | Wuxi Apptec (Shanghai) Co., Ltd. | A novel aav variant |
| CN114787180A (zh) | 2019-10-17 | 2022-07-22 | 斯特里迪比奥公司 | 用于治疗c型尼曼-匹克病的腺相关病毒载体 |
| MX2022004353A (es) | 2019-10-17 | 2022-07-19 | Casete de transferencia de aav. | |
| US20230340078A1 (en) | 2019-11-14 | 2023-10-26 | Biomarin Pharmaceutical Inc. | Treatment of hereditary angioedema with liver-specific gene therapy vectors |
| CA3168055A1 (en) | 2020-02-21 | 2021-08-26 | Emmanuel John Simons | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| TW202142554A (zh) * | 2020-02-25 | 2021-11-16 | 澳洲兒童醫學研究所 | 腺相關病毒蛋白殼多肽及載體 |
| WO2021183895A1 (en) | 2020-03-13 | 2021-09-16 | Biomarin Pharmaceutical Inc. | Treatment of fabry disease with aav gene therapy vectors |
| TW202144575A (zh) | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | 使用ａａｖ及治療調配物之苯酮尿症治療 |
| AU2021259422A1 (en) | 2020-04-20 | 2022-12-08 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
| US11535868B2 (en) | 2020-04-29 | 2022-12-27 | Bristol-Myers Squibb Company | Miniaturized dystrophins having spectrin fusion domains and uses thereof |
| WO2021236908A2 (en) | 2020-05-20 | 2021-11-25 | Biomarin Pharmaceutical Inc. | Use of regulatory proteins for the production of adeno-associated virus |
| US20230242905A1 (en) * | 2020-07-03 | 2023-08-03 | Genethon | Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions Swapping |
| JP2023542614A (ja) | 2020-08-19 | 2023-10-11 | サレプタ セラピューティクス， インコーポレイテッド | レット症候群の治療のためのアデノ随伴ウイルスベクター |
| CN116096431A (zh) * | 2020-09-10 | 2023-05-09 | 吉尼松公司 | 肽修饰的aav衣壳 |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| WO2022082109A1 (en) * | 2020-10-18 | 2022-04-21 | The Trustees Of The University Of Pennsylvania | Improved adeno-associated virus (aav) vector and uses therefor |
| KR20230078805A (ko) | 2020-11-02 | 2023-06-02 | 바이오마린 파머수티컬 인크. | 아데노-연관 바이러스의 농축 공정 |
| JP2024534894A (ja) | 2021-09-03 | 2024-09-26 | ビオマリン プハルマセウトイカル インコーポレイテッド | Ａａｖカプシド組成物及び送達方法 |
| WO2023034990A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| EP4396201A1 (en) | 2021-09-03 | 2024-07-10 | BioMarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| WO2023034980A1 (en) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| WO2023034989A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| US20240384242A1 (en) | 2021-09-03 | 2024-11-21 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| TW202332472A (zh) | 2021-10-01 | 2023-08-16 | 美商拜奧馬林製藥公司 | 利用ａａｖ基因療法載體進行之遺傳性血管水腫治療及治療性調配物 |
| CN114276419B (zh) * | 2021-12-30 | 2023-11-17 | 上海勉亦生物科技有限公司 | 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用 |
| US20250213727A1 (en) * | 2022-03-25 | 2025-07-03 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| UY40442A (es) | 2022-09-22 | 2024-02-15 | Biomarin Pharm Inc | Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav |
| UY40443A (es) | 2022-09-22 | 2024-02-15 | Biomarin Pharm Inc | Tratamiento de la miocardiopatía con vectores de genoterapia con aav |
| CN115925819B (zh) * | 2022-12-30 | 2023-10-13 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2025051970A2 (en) | 2023-09-06 | 2025-03-13 | Dinaqor Ag | Methods of treatment of hypertrophic cardiomyopathy with aav gene therapy vectors and therapeutic formulations |
| EP4774005A1 (en) * | 2023-09-08 | 2026-07-15 | California Institute of Technology | Compositions for transport of therapeutic cargos using miniprotein binders targeting ca-iv |
| CN122514808A (zh) * | 2023-11-17 | 2026-08-04 | 吉尼松公司 | 通过深度学习预测多种aav特性 |
| WO2025214477A1 (en) | 2024-04-12 | 2025-10-16 | Skyline Therapeutics (Shanghai) Co., Ltd. | Treatment of genetic cardiomyopathies with aav gene therapy vectors |
| WO2025250683A1 (en) * | 2024-05-29 | 2025-12-04 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| EP0127839B1 (en) | 1983-05-27 | 1992-07-15 | THE TEXAS A&M UNIVERSITY SYSTEM | Method for producing a recombinant baculovirus expression vector |
| DK518384A (da) | 1984-01-31 | 1985-07-01 | Idaho Res Found | Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| RU2273645C9 (ru) | 1994-08-17 | 2006-11-27 | Дзе Рокефеллер Юниверсити | Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| EP0933997A4 (en) | 1996-09-06 | 2000-08-16 | Chiron Corp | METHODS AND COMPOSITIONS FOR LIVER-SPECIFIC ADMINISTRATION OF THERAPEUTIC MOLECULES USING RECOMBINANT AAV VECTORS |
| CA2264482A1 (en) | 1996-09-06 | 1998-03-12 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター |
| US7323324B2 (en) | 2001-10-16 | 2008-01-29 | National Institute Of Advanced Industrial Science And Technology | N-Acetylglucosamine transferase, nucleic acid encoding the same, antibody against the same and use thereof for diagnosing cancer or tumor |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| EP1463805B1 (en) | 2001-12-17 | 2014-10-22 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| WO2003074714A1 (en) | 2002-03-05 | 2003-09-12 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
| US20030198620A1 (en) | 2002-04-16 | 2003-10-23 | Keiya Ozawa | Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions |
| WO2003093436A2 (en) | 2002-04-30 | 2003-11-13 | University Of Florida | Treatment for phenylketonuria |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| WO2006073496A2 (en) | 2004-07-30 | 2006-07-13 | Targeted Genetics Corporation | Recombinant aav based vaccine methods |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| US8283151B2 (en) * | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| WO2008088895A2 (en) | 2007-01-18 | 2008-07-24 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
| AR066354A1 (es) | 2007-05-01 | 2009-08-12 | Genzyme Corp | La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica |
| HUE029744T2 (en) * | 2007-07-26 | 2017-04-28 | Uniqure Ip Bv | Baculoviral vectors comprising repeated coding sequences with differential codon biases |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2009088979A1 (en) | 2008-01-07 | 2009-07-16 | Biomarin Pharmaceutical Inc. | Method of synthesizing tetrahydrobiopterin |
| ES2579231T3 (es) | 2008-01-15 | 2016-08-08 | Abbvie Inc | Vectores de expresión de mamíferos mejorados y usos de los mismos |
| US7943379B2 (en) | 2008-04-30 | 2011-05-17 | Nationwide Children's Hospital, Inc. | Production of rAAV in vero cells using particular adenovirus helpers |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| ES2985035T3 (es) | 2008-09-15 | 2024-11-04 | Uniqure Biopharma B V | Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción |
| DK2425000T3 (da) | 2009-04-30 | 2019-05-13 | Univ Pennsylvania | Sammensætninger rettet mod ledende luftvejsceller omfattende konstrukter af adeno-associeret virus |
| GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| EP2550359B1 (en) | 2010-03-23 | 2017-08-09 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| WO2011126808A2 (en) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
| BR112014020325A2 (pt) | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| GB201210357D0 (en) | 2012-06-12 | 2012-07-25 | Ucl Business Plc | Factor VIII sequences |
| BR112015021036A2 (pt) | 2013-03-15 | 2017-10-10 | Univ Pennsylvania | composições e métodos para tratar mps1 |
| US11136557B2 (en) | 2013-05-31 | 2021-10-05 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
| NZ716102A (en) | 2013-07-22 | 2021-12-24 | The Children’S Hospital Of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| ES2813698T3 (es) | 2013-09-12 | 2021-03-24 | Biomarin Pharm Inc | Vectores de AAV que comprenden un gen que codifica el factor VIII |
| HUE052676T2 (hu) * | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| BR112016020688B1 (pt) | 2014-03-09 | 2024-01-30 | The Trustees Of The University Of Pennsylvania | Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos |
| EP2960336A1 (en) | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
| WO2016004318A1 (en) | 2014-07-02 | 2016-01-07 | Shire Human Genetic Therapies, Inc. | Encapsulation of messenger rna |
| US10301367B2 (en) | 2014-07-26 | 2019-05-28 | Consiglio Nazionale Delle Ricerche | Compositions and methods for treatment of muscular dystrophy |
| WO2016049230A1 (en) * | 2014-09-24 | 2016-03-31 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
| GB201507842D0 (en) | 2015-05-07 | 2015-06-17 | New Royal Holloway & Bedford | Production of large-sized microdystrophins in an AAV-based vector configuration |
| EP4134375A1 (en) | 2015-07-30 | 2023-02-15 | Massachusetts Eye & Ear Infirmary | Ancestral adeno associated virus sequences and uses thereof |
| JP2018535929A (ja) | 2015-09-24 | 2018-12-06 | バイオマリン ファーマシューティカル インコーポレイテッド | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
| WO2017066764A2 (en) * | 2015-10-16 | 2017-04-20 | William Marsh Rice University | Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses |
| US10143760B2 (en) | 2015-10-28 | 2018-12-04 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| CN110300591A (zh) | 2016-11-04 | 2019-10-01 | 百深公司 | 腺相关病毒制剂 |
| EP3562494A4 (en) | 2016-12-30 | 2020-08-19 | The Trustees Of The University Of Pennsylvania | GENE THERAPY FOR THE TREATMENT OF PHENYLKETONURIS |
| WO2019152841A1 (en) | 2018-02-01 | 2019-08-08 | Homology Medicines, Inc. | Adeno-associated virus compositions for pah gene transfer and methods of use thereof |
| KR20210008501A (ko) | 2018-05-09 | 2021-01-22 | 바이오마린 파머수티컬 인크. | 페닐케톤뇨증을 치료하는 방법 |
| CN112424345A (zh) | 2018-05-14 | 2021-02-26 | 生物马林药物股份有限公司 | Aav载体在青少年对象中的稳定表达 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| JP7630443B2 (ja) | 2019-04-19 | 2025-02-17 | レジェンクスバイオ インコーポレーテッド | アデノ随伴ウイルスベクター製剤及び方法 |
| WO2020232044A1 (en) | 2019-05-14 | 2020-11-19 | Biomarin Pharmaceutical Inc. | Methods of redosing gene therapy vectors |
| TW202144575A (zh) | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | 使用ａａｖ及治療調配物之苯酮尿症治療 |
-
2017
- 2017-07-25 JP JP2019503445A patent/JP6994018B2/ja not_active Expired - Fee Related
- 2017-07-25 BR BR112019001532-9A patent/BR112019001532A2/pt unknown
- 2017-07-25 EP EP17749265.9A patent/EP3491008A2/en not_active Withdrawn
- 2017-07-25 US US16/319,877 patent/US11584780B2/en active Active
- 2017-07-25 KR KR1020237039466A patent/KR20230161535A/ko not_active Abandoned
- 2017-07-25 KR KR1020197001930A patent/KR102604510B1/ko active Active
- 2017-07-25 WO PCT/US2017/043703 patent/WO2018022608A2/en not_active Ceased
- 2017-07-25 MX MX2019000962A patent/MX2019000962A/es unknown
- 2017-07-25 CA CA3031026A patent/CA3031026A1/en active Pending
- 2017-07-25 CN CN201780045741.3A patent/CN109715650B/zh not_active Expired - Fee Related
- 2017-07-25 SG SG11201811603WA patent/SG11201811603WA/en unknown
- 2017-07-25 IL IL263801A patent/IL263801B2/en unknown
- 2017-07-25 AU AU2017301600A patent/AU2017301600B2/en not_active Ceased
- 2017-07-25 PE PE2019000266A patent/PE20190401A1/es unknown
- 2017-07-25 IL IL305149A patent/IL305149A/en unknown
-
2019
- 2019-01-10 PH PH12019500068A patent/PH12019500068A1/en unknown
- 2019-01-22 CL CL2019000167A patent/CL2019000167A1/es unknown
-
2020
- 2020-12-04 CL CL2020003176A patent/CL2020003176A1/es unknown
-
2021
- 2021-10-07 JP JP2021165270A patent/JP7395550B2/ja active Active
- 2021-12-29 JP JP2021215368A patent/JP7303287B2/ja active Active
-
2022
- 2022-10-27 AU AU2022259813A patent/AU2022259813A1/en not_active Abandoned
- 2022-12-08 US US18/063,589 patent/US20230322864A1/en not_active Abandoned
-
2023
- 2023-01-18 CL CL2023000165A patent/CL2023000165A1/es unknown
- 2023-04-04 JP JP2023060936A patent/JP2023076606A/ja active Pending
- 2023-09-15 CL CL2023002764A patent/CL2023002764A1/es unknown
- 2023-10-06 CL CL2023003001A patent/CL2023003001A1/es unknown
- 2023-10-06 CL CL2023003010A patent/CL2023003010A1/es unknown
-
2024
- 2024-05-28 US US18/676,309 patent/US20240317813A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500068A1 (en) | Novel adeno-associated virus capsid proteins | |
| PH12020551938A1 (en) | Liver targeting adeno-associated viral vectors | |
| PH12018500594A1 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
| MX2018006840A (es) | Focalizacion de peptidos para dirigir virus adenoasociados. | |
| UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
| WO2017189964A3 (en) | Compositions for the treatment of disease | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
| EA201890640A1 (ru) | Рекомбинантные векторы, содержащие пептид 2а | |
| EP3575398A4 (en) | ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT | |
| AU2018260998A1 (en) | Modulatory polynucleotides | |
| MX2018007234A (es) | Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal. | |
| NZ727020A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| MX2019004784A (es) | Metodos de purificacion del virus adeno-asociado. | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
| EP3710046A4 (en) | RECOMBINANT VECTORS CODING FOR PROTEIN SUBUNITIES OF THE ZIKA VIRUS | |
| EA202191919A1 (ru) | Неоантигены предстательной железы и их применение | |
| HK40009350A (en) | Novel adeno-associated virus capsid proteins |